Envoy Medical Business Summary

Envoy Medical, Inc. (COCH) is a clinical-stage medical technology company specializing in fully implanted hearing solutions designed to eliminate the need for external hardware. The company primarily generates revenue through the sale and maintenance of its FDA-approved Esteem® active middle ear implant, though it is currently transitioning toward a high-growth commercialization model centered on its flagship Acclaim® Cochlear Implant (CI). The Acclaim CI, which is currently in late-stage pivotal clinical trials as of early 2026, represents the company's primary business segment and future value driver. Envoy Medical competes directly with established industry giants Cochlear Limited, MED-EL, and Advanced Bionics (Sonova). Unlike these competitors, whose devices require bulky external sound processors and magnets, Envoy positions itself as a premium disruptor by offering the only fully internal system that utilizes the ear’s natural anatomy to capture sound. The company is led by CEO Brent Lucas, who has been with the organization since 2007 and rose from an intern to chief executive in 2015, bringing a specialized background in medical device law and business development. The technical leadership is anchored by Tom Hoegh, Vice President of Research and Development, a veteran with over 30 years of experience in active implantable devices from firms such as Medtronic and Nuvectra. Financial oversight is managed by Interim CFO Robert Potashnick, while Karin Simonson serves as VP and General Counsel. The company’s strategic direction is heavily influenced by its largest shareholder and board member, Glen A. Taylor (owner of the Minnesota Timberwolves), alongside institutional backing from Nantahala Capital and Broadfin Holdings. The board is chaired by Charles Brynelsen, a seasoned executive with extensive experience in the global medical device sector.